Meta-Flux
Meta-Flux provides an AI-powered platform that simulates disease biology to speed up drug development. It integrates genetic, protein, and metabolic data using multi-scale models and knowledge graphs to generate ranked hypothesis summaries and drug-repurposing opportunities. The system supports adaptive experimentation for pharmaceutical teams and focuses on early-stage research decisions. Core technologies include AI modeling, multi-omics data fusion, multi-scale simulations, and graph-based reasoning. As a B2B platform for biopharma, it targets fast scaling of discovery pipelines and clearer go/no-go decisions.
Meta-Flux
Meta-Flux provides an AI-powered platform that simulates disease biology to speed up drug development. It integrates genetic, protein, and metabolic data using multi-scale models and knowledge graphs to generate ranked hypothesis summaries and drug-repurposing opportunities. The system supports adaptive experimentation for pharmaceutical teams and focuses on early-stage research decisions. Core technologies include AI modeling, multi-omics data fusion, multi-scale simulations, and graph-based reasoning. As a B2B platform for biopharma, it targets fast scaling of discovery pipelines and clearer go/no-go decisions.
TL;DR
What they do: AI platform for in silico disease biology to accelerate preclinical R&D and drug-repurposing
Headquarters: Dublin, Ireland
Stage & size: Early-stage (pre-seed/seed); team size ~1–10
Founders: Lee Sherlock; Brendan Martin; Sinah Behsanger
Founded: 2020–2021 (sources list both years)
Company Overview
Problem Domain
Preclinical drug discovery, disease modeling, and drug-repurposing decision support
Founded
2021
Industry
Biotechnology